|
The market opportunity The cancer therapy market in general is one of the fastest growing drug sectors, accounting for over one-third of all pharmaceutical sales worldwide. Oncology drug sales by 2009 are expected to reach $55 billion compared to the $30 billion level reached in 2004. Incidences of skin cancer and melanoma are increasing worldwide with the market expected to continue growing.
Cyplasin-SC, currently in pre-clinical testing has been shown to be effective at targeting skin cancer and melanoma cancer cells whereas normal cells were not affected. Cyplasin-SC will be applied to the skin within the tumor’s vicinity. Once the Cyplasin-SC Investigational New drug Application (IND) is submitted to the FDA, research programs and preclinical development for other cancer applications will be initiated. The company has secured sufficient funding to initiate and complete the preclinical program for Cyplasin-SC. In addition, the Company has attracted the required management, board members and scientific advisory members that are the other success components for the overall development of the products within Cyplasin Biomedical Ltd. Sales of anti-cancer drugs are expected to reach $55 billion by 2009 worldwide, with over $600 million of that in the treatment of melanoma. Cyplasin-SC is positioned to make a significant impact with products especially designed to treat skin cancers and melanoma. |
Cyplasin Biomedical Ltd. will focus on bringing a pipeline of Cyplasin™ based products to market to treat cancer. Cyplasin Biomedical’s current mission is to first develop Cyplasin-SC™ for skin cancers and melanoma and then evaluate its use for other cancers. Cyplasin Biomedical Ltd. is advancing its pre-clinical program in order to submit an Investigational New Drug (IND) application for Cyplasin-SC which upon successful approval would allow the initiation of human clinical trials.|
Sales of anti-cancer drugs are expected to reach $55 billion by 2009 worldwide, with over $600 million of that in the treatment of melanoma. Cyplasin is positioned to make a significant impact with products especially designed to treat skin cancers and melanoma. |